Compare CARE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CARE | TRDA |
|---|---|---|
| Founded | 1974 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.9M | 481.6M |
| IPO Year | 2020 | 2021 |
| Metric | CARE | TRDA |
|---|---|---|
| Price | $20.11 | $12.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 159.0K | ★ 192.4K |
| Earning Date | 04-30-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.19 | N/A |
| EPS | ★ 1.38 | N/A |
| Revenue | $20,315,000.00 | ★ $25,421,000.00 |
| Revenue This Year | $12.50 | $39.97 |
| Revenue Next Year | $9.72 | $53.29 |
| P/E Ratio | $14.57 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $13.61 | $4.93 |
| 52 Week High | $22.51 | $13.66 |
| Indicator | CARE | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 35.78 | 57.31 |
| Support Level | $19.32 | $9.78 |
| Resistance Level | $20.36 | N/A |
| Average True Range (ATR) | 0.60 | 0.91 |
| MACD | -0.17 | 0.14 |
| Stochastic Oscillator | 21.29 | 67.11 |
Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.